MSH2 Deletion/Duplication Analysis
Use
GlycA is hypothesized to be a nonspecific measure of global inflammation status. Unlike existing biomarkers of inflammation that are discrete molecular species, such as CRP or inflammatory cytokines, GlycA is a composite biomarker that integrates the protein levels and glycosylation states of several of the most abundant acute- phase proteins in serum. This allows for a more stable measure of systemic inflammation with lower intra-individual variability of GlycA than hsCRP. While guidelines recommend two serial measurements be taken at least two weeks apart when using hsCRP for CV disease risk assessment, only one measurement is necessary for evaluation of a patient's CV risk using the GlycA test.
Special Instructions
Not provided.
Limitations
If triglyceride level is >800 mg/dL, LDL cholesterol will not be calculated.
Methodology
Nuclear magnetic resonance (NMR)
Biomarkers
LOINC Codes
- 2093-3
- 2571-8
- 2085-9
- 43396-1
- 13457-7
- 82730-3
- 94560-0
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Unknown
Volume
Not provided
Minimum Volume
Not provided
Patient Preparation
Patient fasting is not required; however, in conditions where triglyceride values provide a priori diagnostic information, such as screening for familial hypercholesterolemia or early onset heart disease, pancreatitis, or confirming hypertriglyceridemia, the patient should be counseled to fast 12 to 14 hours prior to blood draw.
Causes for Rejection
Unspun LipoTube or unseparated plain red-top or EDTA tube; serum or plasma specimen drawn in gel-barrier collection tube other than the NMR LipoTube; hemolysis (may reduce GlycA concentrations more than 10%)